FDA approves berotralstat (Orladeyo) to prevent attacks of hereditary angioedema

The approval for use in adults and young patients aged years and older, was based on data from the phase 3 APeX-2 trial, which showed that berotralstat could significantly reduce attacks at the 24-week mark, which was sustained through 48 weeks in the study.

Biospace Inc.